Secretory component and lactoferrin in pure pancreatic juice in chronic pancreatitis

To evaluate pathophysiological roles of proteins in pancreatic secretion, immunoreactive lactoferrin (LF) and secretory component (SC) were measured in the first fraction of the pure pancreatic juice obtained endoscopically from 17 control, 21 suspected (SCP), 14 noncalcified (NCP), and 14 calcified chronic pancreatitis (CCP) subjects. The protein and amylase tended to decrease both in concentration and output from control to CCP. LF concentration was elevated in CCP (18.0±4.9/ml) when compared with controls (2.3±0.2g/ml), and LF output in NCP (12.3±3.8 g/min) was increased from controls (3.8±0.6 g/min). The combination of high LF concentration with low protein output was observed in 10/14 in CCP but 0/14 in NCP and can be a biochemical discriminator of CCP from NCP. SC concentrations were also elevated in NCP (8.5±2.0 g/ml) and CCP (5.6±1.6 g/ml) from controls (1.2±0.2 g/ml). SC outputs in SCP (9.8±3.1 g/min) and NCP (21.1±4.8 g/min) were increased from controls (1.7±0.3 g/min), but there was no further increase in CCP. Hypersecretion of LF and SC in chronic pancreatitis is different, especially in CCP, although the mechanisms for hypersecretion are unknown.This study was supported in part by a research grant for intractable pancreatic disease from the Ministry of Health and Welfare, Japan.     

Islet B-cell dysfunction and the time course of recovery following chronic overinsulinisation of normal rats

Summary Appropriate insulin therapy may preserve or improve islet B-cell function whereas the effects of overinsulinisation are unclear. Pancreatic islet B-cell function was therefore studied after overinsulinisation of normal rats for 4 weeks (fed blood glucose 2.2–4.5 mmol/l, controls 4.1–7.0 mmol/l). Insulin secretion was assessed by a 3-h hyperglycaemic clamp (10.0 mmol/l) performed 1, 48, and 120 h after insulin withdrawal (n=6 in each group). When the clamp was performed 1 h after insulin withdrawal, clamp insulin concentration was 1.6±0.1 g/l, compared to 9.3±1.0 g/l in control rats. The integrated area under the plasma insulin concentration curve was also significantly decreased (4.8±0.4 vs 20.3±2.2 g·l^–1·h^–1, p<0.001), but recovered to 9.4±1.0 g·l^–1·h^–1 after 48 h, and to 17.5±1.4 g·l^–1·h^–1 after 120 h. Pancreatic insulin contents were decreased at 1 h (6±1 g/g wet wt) and 48 h (54±12 g/g wet wt) but not at 120 h (221±30 g/g wet wt) after withdrawal (controls, 303±29 /g wet wt) and there was a strong relationship with pancreatic preproinsulin mRNA and the clamp insulin response. Thus, overinsulinisation with prolonged periods of low blood glucose concentrations impairs islet B-cell function, but is reversible over 5 days.     

Pharmacological evidence for beta3 adrenoceptors in the control of rat gastric acid secretion

The effect of the ₃-adrenoceptor agonist BRL37344 on gastric acid secretion evoked by different secretory stimuli was investigated in anaesthetized rats with lumen-perfused stomachs in comparison with the ₂-adrenoceptor agonist clenbuterol. Intravenous injections of BRL37344 (1–10 mol/kg) and clenbuterol (0.01–1 mol/kg) dose-dependently reduced 2-deoxy-D-glucose-induced acid secretion, with BRL37344 about forty times less potent than clenbuterol. BRL37344 (0.1–3 mol/kg) inhibited pentagastrin-induced acid output, whereas clenbuterol was effective only at high doses (10–100 mol/kg). The inhibitory effect of BRL37344 on pentagastrin-induced acid secretion was not modified by the nonselective –adrenoceptor antagonist propranolol, but it was prevented by bupranolol, a ₃-adrenoceptor antagonist. Furthermore, neither BRL37344 (10 mol/kg) nor clenbuterol (100 mol/kg) modified the acid secretion induced by histamine. These data suggest that ₃ adrenoceptors have an inhibitory role in the control of rat gastric acid secretion induced by indirect stimuli.     

High plasma leucine concentrations without neurological symptoms in a patient with classical maple syrup urine disease

It has been found that the amino acid analyser used in this study systematically overestimated plasma leucine at high concentrations. The concentration reported as 2249 mol/L had a true value of 1430 mol/L and leucine values reported as >2000 mol/L were approximately 1500 mol/L.     

Cellular ionic effects of insulin in normal human erythrocytes: a nuclear magnetic resonance study

Summary Elevated erythrocyte cytosolic free calcium, and suppressed free magnesium and pH values are associated with the hyperinsulinaemia and insulin resistance of hypertension, obesity, and Type 2 (non-insulin-dependent) diabetes mellitus. To determine the role of insulin in this process, we utilized ¹⁹F- and ³¹P-nuclear magnetic resonance spectroscopy to study the cellular ionic effects of insulin in vitro on normal human erythrocytes. Insulin elevated cytosolic free calcium levels in a dose- and time-dependent manner. The effect began at 10 U/ml, peaked at 200 U/ml, and continued at both the 500 U/ml and 1000 U/ml doses. At 200 U/ml, free calcium levels rose from 24.6±2.5 nmol/l to a peak value at 120 min of 66.4±11 nmol/l (p<0.05 vs basal), levels remaining elevated throughout the incubation (45.7±5.6 nmol/l at 60 min, and 47.9±9.1 nmol/l at 180 min, p<0.05 vs basal, respectively). Similarly, insulin also increased intracellular free magnesium at all time points (basal: 177± 11 mol/l; 60 min: 209±19 mol/l; 120 min: 206±22 mol/l; and 180 min: 202±12 mol/l; p<0.05 vs basal at all times). No insulin-induced changes in pH were observed. We conclude (i) that insulin in physiological concentrations may participate in regulating divalent cations in the mature human erythrocyte, (ii) that insulin per se cannot account for the previously described cellular ionic lesions of hypertension and diabetes, and (iii) that future clinical studies of cell ion metabolism should be conducted in the fasting state, be controlled for ambient circulating insulin levels, or both.     

Tannin inhibition of protein kinase C in airway epithelium

Tannin, a polydisperse polyphenol extracted from cotton bracts (CBE), has been implicated in the pathogenesis of byssinosis, a lung disease of mill workers. CBE tannin inhibits chloride secretion in airway epithelial cells by means of an unknown mechanism(s). Activation of protein kinase C (PKC) by PMA (phorbol 12-myristate 13-acetate) in airway cells increases chloride secretion. The effect of tannin on this PKC pathway was examined, using canine tracheal epithelium mounted in Ussing chambers. PMA addition (10 nM) to the mucosal bath resulted in a 0.36 ± 0.07 Eq/cm² · h (mean ± SEM, n = 20) increase in short-circuit current (I_sc) and a 0.38 ± 0.17 Eq/cm² · h increase in net chloride secretion (J_net). The inactive 4-phorbol had no effect. Tannin addition to the mucosal bath produced a dose-dependent decrease in I_sc and J_net. In tissues pretreated with 2–50 g/ml tannin, and subsequently stimulated with PMA, tannin inhibited PMA stimulation of chloride secretion beginning at a tannin concentration of 10 g/ml (0.09 ± 0.05 Eq/cm² · h [n = 10] increase in I_sc and 0.08 ± 0.03 Eq/cm² · h increase in J_net with PMA after tannin pretreatment). At 50 g/ml tannin, the stimulatory effect of PMA was completely abolished. The known PKC inhibitor, H-7 (20 M), inhibited PMA stimulation, while chelerythrine (2 M) had not effect on PMA-stimulated I_sc and J_net, and calphostin C was toxic to the airway epithelium. In membrane fragments, 2.5 g/ml tannin inhibited the rate of histone III phosphorylation by PMA from 32.1 ± 4.4 nmol/mg protein per min to 20.1 ± 2.7 nmol/mg protein per min (n = 7). In bovine airway cells, tannin pretreatment (2.5 g/ml) decreased the cytosolic activity of PKC but had no effect on PKC translocation to the membrane. We conclude that tannin inhibits chloride secretion in airway epithelial cells in part by inhibiting PKC.Offprint requests to: Michelle M. Cloutier     

Inhibition of biliary phospholipid and cholesterol secretion by cefoperazone

The effect of cefoperazone, a third-generation cephalosporin, on biliary lipid secretion in rats was examined. Rats were anesthetized with ether and the mid-lumbar vein and common bile duct cannulated. Bile acid secretion was maintained by intravenous taurocholic acid infusion (28 mol/hr). A 1-hr control period was followed by intravenous cefoperazone infusion at either submaximal (20 mol/hr), or supramaximal (60 mol/hr) concentrations. At the cefoperazone infusion rate of 20 mol/hr (biliary secretion of 7.1±1.6 mol/hr) phospholipid secretion fell 19% and cholesterol secretion fell 31%; at a cefoperazone infusion rate of 60 mol/hr (biliary secretion rate of 27.1±5.1 mol/hr) phospholipid and cholesterol secretion were further reduced 40% and 56%, respectively, of controls. All changes were significant (P<0.01). Inhibition of both cholesterol and phospholipid secretion paralleled each other, was dose-dependent, and reversible. Cefoperazone's inhibitory action was abolished at a bile acid infusion rate of 108 mol/hr. Cefoperazone was not found to be associated with bile acid micelles or mixed micelles as determined by ultracentrifugation and gel filtration. Thus, the effect of cefoperazone on biliary lipid secretion is not due to the impairment of mixed micelle formation in the canalicular lumen but rather its inhibitory effect appears to be due to a presecretory event.     

Exogenous hyperglucagonaemia in insulin controlled diabetic rats increases urea excretion and nitrogen loss from organs

Summary In order to study the effect of hyperglucagonaemia on nitrogen metabolism in diabetes, zinc protamin glucagon 60 g was injected subcutaneously 3 times daily for 4 weeks into streptozotocindiabetic rats (n=5), adequately treated with long acting insulin. This raised the plasma concentration of glucagon to 725±125 (mean±SEM), which is not different from that found in portal blood of uncontrolled diabetic rats: 400±75 ng/l. The controls were 5 diabetic rats treated with insulin alone and 5 non-diabetic rats.Compared with control rats the nitrogen balance was reduced (p<0.05) and the nitrogen contents of carcass, heart, intestines, and kidneys were reduced by 15–30% (p<0.05) in the glucagon treated rats. The hepatic capacity of urea synthesis and the alanine elimination rate were determined in the 3 above-mentioned groups, and confirmed in 3 identical groups followed for only 2 weeks; and in addition in a group of glucagon treated diabetic rats, where the long acting glucagon was substituted by neutral insulin the last two days before investigation. The capacity of urea-N synthesis and the alanine elimination rate were, respectively, in control rats: 9.6±0.8 and 5.9±0.3 mol/(min 100 g body weight), in insulin treated diabetic rats: 8.5±0.7 and 5.4±0.6 mol/(min 100g body weight), in glucagon treated rats: 6.3±0.4 (lower than controls, p<0.05) and 10.4±0.4 (higher than controls, p<0.05) (mol/(min 100 g body weight), and in glucagon treated rats given neutral insulin: 20.7±1.6 and 10.9±0.3 mol/(min 100 g body weight) (both higher than controls, p<0.05). Hyperglucagonaemia in itself leads to loss of nitrogen from organs, probably by an increased hepatic conversion of amino-nitrogen to urea-nitrogen, as evidenced by the increased urea excretion. This proceeds despite an insulin induced decrease in the capacity of urea synthesis and may thus rather be attributed to changes in the affinity of urea synthesis for amino-nitrogen.     

In vitro kinetics of insulin release by microencapsulated rat islets: effect of the size of the microcapsules

Summary Microencapsulation has been proposed to protect islets of Langerhans against immune rejection in xenogenic transplantation. However, to achieve glucose homeostasis in human diabetic patients, insulin release by microencapsulated islets must increase in response to a glucose load. We microencapsulated isolated rat islets using the alginate-polylysine procedure. Capsule size was found to range from 300 to 800 m, and microencapsulated islets were separated according to their size. Groups of 10 microencapsulated islets, either small (350 m) or large (650 m) were placed in plastic microwells, in minimal Eagle's culture medium containing either 5.5 mol/l glucose (basal) or 16.5 mol/l glucose and 5.5 mol/l theophylline (stimulatory medium). The increase in insulin concentration in the surrounding medium was then serially determined over 30 min: (1) With the small capsules, insulin concentration rose from 199 ±20 to 297 ±58 U/ml in basal medium, and from 236 ±23 to 510 ±121 U/ml in stimulatory medium (n = 10 preparations), the difference between the data obtained with the basal or the stimulatory medium being significant (p<0.01) from the 5th min onwards. (2) With large capsules, insulin concentration increased from 182±9 to 266±44 U/ml, and from 216 ±19 to 297 ±34 U/ml in basal and stimulatory medium, respectively, with no apparent significant difference. The magnitude of insulin secretion in response to glucose by unencapsulated islets was, under similar conditions, seven-fold greater. We conclude therefore that the size of the microcapsules is an essential parameter which has to be considered for the optimisation of the microencapsulation procedure.     

Adenosine-induced increase in myocardinal ATP: Are there beneficial effects for the ischaemic myocardium?

Summary The adenosine triphosphate (ATP) content of isolated Langendorff-perfused rat hearts may be increased by more than 40% above the normal value by a 2-h perfusion with adenosine (15 mol/l). This metabolic manipulation was used to investigate the hypothetical relationship between total tissue ATP content and ischaemia-induced contractile failure, ischaemic contracture and post-ischaemic functional recovery.Adenosine perfused hearts were submitted to 20 min of normothermic ischaemia and reperfused for 45 min with or without adenosine. Control experiments were performed with adenosine-free preischaemic perfusion. In identically designed experiments the tissue-protective effect of diltiazem (0.5 mol/l) was determined and compared with the experiments with adenosine.At the end of 120 min of preischaemic perfusion, the ATP content of the adenosine treated hearts was 34.3±1.8 mol/g dry weight (control=23.6±1.9 mol/g, p<0.01). After a period of 20 min of normothermic ischaemia, the ATP content of the adenosine hearts decreased to 13.3± .4 mol/g, whereas ATP fell to 8.3±1.6 mol/g in the control hearts. The creatine phosphate (CP) levels of adenosine hearts were significantly lower than those of the control group before ischaemia, but did not show major differences following ischaemia.During ischaemia, the contractile activity measured via an intraventricular balloon catheter, as well as ischaemic contracture did not differ between the adenosine and control hearts. The inclusion of diltiazem into the perfusate significantly delayed the onset of contracture.After 45 min of reperfusion, ATP contents of adenosine and control hearts reached similar values (8.4±2.3 and 8.3±2.9 mol/g, respectively). Inclusion of adenosine (15 mol/l in the reperfusion perfusate of the adenosine experiments prevented a further decrease, but did not increase tissue ATP content. CP values of all groups showed a partial recovery upon reperfusion, they did not differ significantly.Contractile recovery was equal in all experimental groups except for the diltiazem treated hearts, which showed during the first 10 min of reperfusion an improved mechanical performance.It is concluded that total tissue ATP is not necessarily a good indicator of functional capabilities under conditions of normothermic ischaemia and reperfusion in the isolated rat heart.This work was supported in part by grants from the British heart foundation, the British Council and the St. Thomas, Hospital Research Endowments Fund. The advice and assistance of Dr. M. Curtis and Mrs. C. Erlebach are gratefully acknowledged.     

Insulin levels in the umbilical vein and in the umbilical artery of newborns of normal and gestational diabetic mothers

Summary Insulin levels (by double antibody radioimmunological assay) were studied in the venous blood of mothers at vaginal delivery and in the umbilical vein and artery of their newborns. — In 14 normal mothers the insulin levels after 10 hours fasting were 18.5±3.6 U/ml (mean±S.E.M.). In their newborns (mean: 3.420 kg, all < 4.000 kg, 38–41 weeks gestation) the insulin levels were low and similar in the umbilical vein (5.6±0.7 U/ml) and in the umbilical artery (6.6±0.7 U/ml). The plasma glucose levels in the mothers were 99.7±3.9 mg/100 ml and in the umbilical vein 77.3±3.7 mg/100 ml and the umbilical artery 65.5±3.2 mg/100 ml. They were significantly different from each other. — Eleven normal mothers receiving a glucose infusion (ca. 15 g/3 hours) during delivery had 42.0±9.9 U/ml insulin in their venous blood. In their newborns with a normal birth-weight (mean: 3.585 kg, all < 4.000 kg) the insulin levels were not increased either in the umbilical vein (7.0±1.0 U/ml) or in the artery (7.9±1.0 U/ml). The plasma glucose levels in the mothers were 128.0±7.7 mg/100 ml, and in the umbilical vein 105.0±7.5 mg/ 100 ml and in the umbilical artery 88.8±8.6 mg/100 ml. The plasma glucose levels were significantly different from each other. — In six infants with large birthweight (> 4.100 kg) born to untreated mothers with gestational diabetes the insulin levels were superior to the values found in normal newborns. In three of these infants, born to mothers who did not receive a glucose infusion, the insulin levels in the umbilical vein were 38, 42 and 13 U/ml, and in the artery they were 17, 34.5 and 18.5 U/ml. The other three mothers received a glucose infusion, their newborns had in the umbilical vein an insulin level of 15.5, 65 and 19 U/ml and in the artery 20, 72.5 and 14 U/ml. — In conclusion, the normal infant at birth has a low insulin level, which is equal in the umbilical vein and artery. In 6 heavy infants born to untreated latent diabetic mothers, the insulin levels were significantly higher than in normals, and the levels in the umbilical vein and the artery were different from one another. This latter data on hyperinsulinism is discussed in relation with hyperplasia of the islets of Langerhans observed in stillborn infants of mothers with insulin-dependant diabetes or gestational diabetes.Aspirant du Fonds National de la Recherche Scientifique     

Iron stores in 1359, 30- to 60-year-old Danish women: Evaluation by serum ferritin and hemoglobin

Summary Iron status, including serum (S-)ferritin and hemoglobin (Hb), was assessed in a population survey comprising 1359 nonpregnant Danish women in age cohorts of 30, 40, 50, and 60 years. S-ferritin levels were similar in 30- and 40-year-old women; they displayed a significant increase in 50-year-old women and a further significant increase in 60-year-old women. In the 30- and 40-year-old women, median S-ferritin was 38g/l, 5–95 percentile 6–135g/l; 17.2% had values < 15,g/l (i.e., depleted iron stores), 22.7% values from 15 to 30g/l (i.e., small iron stores), and 60.1% values > 30g/l (i.e., replete iron stores). In the 50-year-old women, median S-ferritin was 54g/l, 5–95 percentile 10–164g/l; 10.3% had values < 15g/l, 16.5% values from 15 to 30g/l, and 73.2% values > 30g/l. For the 60-year-old women, median S-ferritin was 84g/l, 5–95 percentile 25–249g/l; 1.6% had values < 15g/l, 8.6% values from 15 to 30g/l, and 89.8% values > 30g/l. Blood donors (n=180) had lower S-ferritin than nondonors in all age-groups (p<0.001). In the entire series, Hb levels were similar in 30- and 40-year-old women, median 137 g/l (8.5 mmol/l), 5–95 percentile 121–152 g/1 (7.5–9.4 mmol/l), and higher in 50- and 60-year-old women, median 140 g/l (8.7 mmol/l), 5–95 percentile 123-158 g/l (7.6–9.8 mmol/l) (p<0.0001). Hb values < 121 g/l (7.5 mmol/l) were observed in 3.8% of the women. Women with S-ferritin < 15 g/l (n=161) had lower Hb, median 134 g/l (8.3 mmol/l), than those with S-ferritin > 15 g/l, median 139 g/l (8.6 mmol/l) (p<0.001). Iron deficiency anemia (S-ferritin < 15 g/l and Hb < 121 g/l) was seen in 2.3% of 30- and 40-year-old women, and in 1.1% of 50- and 60-year-old women.     

Elevated serum homocysteine levels for gouty patients

Our objective was to analyze serum total homocysteine (tHcy) levels for gouty patients and to study whether there are any level changes following treatment with allopurinol. We enrolled 90 male participants including patients with primary gout (n=51) and community-based healthy controls (n=39). Fasting tHcy levels were determined for all subjects and repeat measurements performed for 29 patients following treatment with allopurinol. The results revealed that gouty patients exhibited significantly greater serum tHcy levels (12.10±3.19 mol/l) than healthy controls did (9.96±2.16 mol/l) (p=0.0003), although there was no obvious difference between the pre-allopurinol treatment group (12.54±3.31 mol/l) and its post-treatment analogue (11.90±4.68 mol/l) (n=29, p=0.33). Elevated serum levels of tHcy were noted for this cohort of male gouty patients as compared to healthy controls, and these tHcy levels did not appear to change substantially following treatment with allopurinol. Although the pathogenesis of hyperhomocysteinemia for gouty patients still remains somewhat obscure, this study suggests that tHcy levels cannot be effectively modulated by treatment with allopurinol.     

Renal proteinases and kidney hypertrophy in experimental diabetes

Summary IDDM is associated with an increase in kidney size, which is due to cellular hypertrophy and progressive matrix accumulation within the glomerulus and throughout the tubulointerstitium. The present study addressed the potential role of cysteine and metalloproteinases in renal hypertrophy of short-term diabetes. Three weeks after induction of streptozotocin diabetes in rats, intraglomerular gelatinase activity (streptozotocin: 23±4 vs control: 44±3 mU/g DNA) and cathepsin L + B activity (streptozotocin: 6.7±0.8 vs control: 9.3±0.7 U/g DNA) were significantly decreased. Insulin treatment completely prevented the decline in glomerular proteinase activity (gelatinase: 37±6 mU/g DNA; cathepsin L + B: 9.6±0.9 U/g DNA). In isolated proximal tubules a similar pattern of enzyme activity could be observed. Three weeks of diabetes caused a significant decline in cathepsin L + B activity (streptozotocin: 28±2 vs control: 37±3 U/g DNA). Insulin treatment again prevented the decline in these tubular proteinase activities. In parallel, kidney weight increased by 22% and glomerular protein/DNA ratio rose by 17% in untreated diabetic rats. Diabetic rats receiving insulin displayed a normal glomerular protein/DNA ratio and the kidney weight was increased by only 5%. These results show that renal hypertrophy of early diabetes is closely associated with a decline in both glomerular and tubular proteinase activity. Adequate insulin substitution prevented renal hypertrophy and the reduction in proteinase activity.Abbreviations AMC 7-Amino-4-methyl coumarin - EDTA ethylene diamine tetra-acetic acid - PMSF phenylmethylsulfonyl fluoride - TGF- transforming growth factor- - TIMP tissue inhibitor of metalloproteinases - GFR glomerular filtration rate - IDDM insulin-dependent diabetes mellitus     

Serumeisen-Normalwerte und statistische Verteilung der Einzelwerte bei Mann und Frau

Zusammenfassung Die Bestimmung der Normalwerte des Serumeisen bei 608 Erwachsenen und die Untersuchung des Verteilungstyps der Einzelwerte zeigt folgende Ergebnisse: Bei 503 Männern beträgt der Mittelwert (als arithmetisches Mittel) 109 g Fe/100 ml ±25 und der Normalbereich (als ±2 SD-Bereich) 59 bis 158 g Fe/100 ml, bei 105 Frauen 91 g Fe/100 ml±27 als Mittelwert und 37 bis 145 g Fe/100 ml als Normalbereich. Die Untersuchung der Verteilung mittelsFisher- undKolmogoroff-Test führte zur Annahme, einer näherungsweisen Normalverteilung.

---

Summary The determination of normal values of serum iron in 608 adults and the examination of the frequency distribution gives the following results: the arithmetic mean in 503 male persons is 109±25 g Fe/100 ml and the normal range (2-SD-range) 59 to 158 g Fe/100 ml; in 105 female persons 91±27 g Fe/100 ml mean and 37 to 145 g Fe/100 ml normal range. The assumption of approximate normal distribution are controlled by theFisher- andKolmogoroff-test.

     

Modulation of pacemaker activity in sheep cardiac Purkinje fibers by stimulation of β-adrenoceptor subtypes

The electrophysiological effects mediated by ₁- and ₂- in spontaneously active sheep cardiac Purkinje fibers were investigated using the non-selective agonist (–)-isoproterenol (IPN) and the selective agonists (–)-noradrenaline (₁) and procaterol (₂) in the absence and presence of the selective antagonists bisoprolol (₁) and ICI 118,551 (₂).IPN (0.01 mol/l) increased the spontaneous rate by 54% and the slope of diastolic depolarization by 68% of the respective control values. Further, IPN increased the action potential duration at –20 mV (APD –20 mV) from 96 to 154 ms, reduced the APD –70 mV by 17% and the duration of the diastole by 39% and slightly hyperpolarized the maximum diastolic potential. These effects were partially inhibited by ICI 118,551 (0.03 mol/l), diminished by bisoprolol (0.1 mol/l) and almost completely blocked by the combination of both antagonists. Concentration response curves of IPN were influenced by the selective antagonists as follows: ICI 118,551 (0.03 mol/l) shifted the curves to the right by 0.2–0.4 log units and increased the slope factor. Bisoprolol (0.1 mol/l) induced a greater shift to the right by 1.1–1.5 log units. Combination of bisoprolol with ICI 118,551 shifted the curves to the right by 1.5–1.7 log units.Noradrenaline (0.3 mol/l) elicited similar actions as IPN. Bisoprolol (0.1 mol/l) shifted the concentration response curves of noradrenaline to the right by 1.1–1.9 log units. Actions of procaterol (0.1 mol/l) were weak, attained only 15–35% of the maximal effects of IPN and could be blocked by ICI 118,551 (0.03 mol/l).These results show that the increase of pacemaker activity induced by catecholamines in sheep cardiac Purkinje fibers is predominantly mediated by stimulation of ₁. However, contribution of ₂ mediated effects could be demonstrated.Supported by Ministerium für Wissenschaft und Forschung, Nordrhein-Westfalen, Projekt-Nr, 40008786.     

Loss of glycogen during preconditioning is not a prerequisite for protection of the rabbit heart

Depletion of gycogen has been proposed as the mechanism of protection from ischemic preconditioning. The hypothesis was tested by seeing whether pharmacological manipublation of preconditioning causes parallel changes in cardiac glycogen content. Five groups of isolated rabbit hearts were studied. Group 1 experienced 30 min of ischemia only. Group 2 (PC) was preconditioned with 5 min of global ischemia followed by 10 min of reperfusion. Group 3 was preconditioned with 5 min exposure to 400 nM bradykinin followed by a 10 min washout period. Group 4 experienced exposure to 10 M adenosine followed by a 10 min washout period, and the fifth group was also preconditioned with 5 min ischemia and 10 min reperfusion but 100 M8-(p-sulfophenyl) theophylline (SPT), which blocks adenosine receptors, was included in the buffer to block preconditioning's protection. Transmural biopsies were taken before treatment, just prior to the 30 min period of global ischemia, and after 30 min of global ischemia. Glycogen in the samples was digested with amyloglucosidase and the resulting glucose was assayed. Baseline glycogen averaged 17.3±0.6 mol glucose/g wet weight. After preconditioning glycogen decreased to 13.3±1.3 mol glucose/g wet weight (p<0.005 vs. baseline). Glycogen was similarly depleted after pharmacological preconditioning with adenosine (14.0±1.0 mol glucose/g wet weight, p<0.05 vs. baseline) suggesting a correlation. However, when proconditioning was performed in the pressence of SPT, which blocks protection, glycogen was also depleted by the same amount (13.3±0.7 mol glucose/g wet weight, p=ns vs. PC). Bradykinin, which also mimics preconditioning, caused no depletion of glycogen (16.3±0.8 mol glucoseig wet weight, p=ns vs. baseline). Because preconditioning with bradykinin did not deplete glycogen and because glycogen continued to be low when protection from preconditioning was blocked with SPT, we conclude that loss of glycogen per se does not cause the protection of preconditioning.     

Dose/response study of the effects of oestrogens on tumour growth and morphology in the Dunning R3327 prostatic adenocarcinoma

Summary The present study was undertaken to investigate to what extent the oestrogen-induced effects on growth and morphology of the Dunning R3327 rat prostatic adenocarcinoma are dose-dependent. Castrated and testosterone-supplemented rats were used in order to study effects of increasing doses of oestrogens on the tumour. It was found that the lowest dose of oestradiol-17 that reduced the overall growth, the volume density of the epithelium and epithelial cell area in Dunning R3327 prostatic tumours is 10 g given as daily injections. Higher oestrogen doses (50 g, 200 g, and 500 g), in addition to reducing the volume of tumour epithelium, also induced an increase of the volume density of tumour stroma. The area of stroma cell nuclei was increased by 50 g and 200 g oestradiol-17. These observation, may indicate that the lowest effective oestrogen dose is different in the epithelium and stroma of Dunning tumours and that large doses of oestrogen stimulate the stromal compartment. This stimulatory effect did not influence the inhibitory effects seen on the overall growth of the tumour and on the tumor epithelium.     

Developmental changes in the fatty (fafa) rat: Evidence for defective thermogenesis preceding the hyperlipogenesis and hyperinsulinaemia

Summary Preobese fatty rats have been identified by their lower rectal temperature. Of 51 pups born from matings of heterozygote (Fafa) parents, 16 had low rectal temperatures from day 16 onward (34.6±0.2° C v 35.4±0.3° C) and all subsequently became obese. No animal with the higher normal rectal temperature developed obesity. Hepatic fatty acid synthesis (preobese 0.6±0.1; lean 0.6±0.1 mol/ g/h), hepatic glucose-6-phosphate dehydrogenase activity (G6PDH) (preobese 0.68±0.07; lean 0.71 ±0.03 mol/g/min) and serum insulin (preobese 64 ±2; lean 58±4 U/ml) were unchanged in 18 day preobese, suckling fafa rats. 3 days after weaning hepatic lipogenesis (preobese 25.3±2.0; lean 5.4±0.7 mol/g/h) and G6PDH activity (preobese 4.5±0.5; lean 0.90±0.05 mol/g/min) had increased in both lean and preobese rats although the values attained in preobese rats were significantly greater than in lean rats. When weaning was delayed there was no enhancement in lipogenesis, G6PDH or serum insulin in the preobese rat. The results suggest that the primary genetic defect in fatty rats is not related to the increase in lipogenesis or serum insulin but may reflect a defective thermogenic process.     

Pharmacokinetics,pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM

Summary The aim of these studies was to compare the pharmacokinetics, pharmacodynamics, counterregulatory hormone and symptom responses, as well as cognitive function during hypoglycaemia induced by s. c. injection of 0.15 IU/kg of regular human insulin (HI) and the monomeric insulin analogue [Lys(B28),Pro (B29)] (MI) in insulin-dependent-diabetic (IDDM) subjects. In these studies glucose was infused whenever needed to prevent decreases in plasma glucose below 3 mmol/l. After MI, plasma insulin increased earlier to a peak (60 vs 90 min) which was greater than after HI (294±24 vs 255±24 pmol/l), and plasma glucose decreased earlier to a 3 mmol/l plateau (60 vs 120 min) (p<0.05). The amount of glucose infused to prevent plasma glucose falling below 3 mmol/l was three times greater after MI than HI (293±26 vs 90±25 mol · kg^–1 · 60–375 min^–1, p<0.05). After MI, hepatic glucose production was more suppressed (0.7±1 vs 5.9±0.54 mol · kg^–1 · min^–1) and glucose utilization was less suppressed than after HI (11.6±0.65 vs 9.1±0.11mol · kg^–1 · min^–1) (p<0.05). Similarly, plasma NEFA, glycerol, and -OH-butyrate were more suppressed after MI than HI (p<0.05), whereas plasma lactate increased only after MI, but not after HI. Responses of counterregulatory hormones, symptoms and deterioration in cognitive function during plasma glucose plateau of 3 mmol/l were superimposable after MI and HI (p=NS). Post-hypoglycaemia hyperglycaemia was greater after MI than HI (at 480 min 12.1±1 vs 11±1 mmol/l) because of greater hepatic glucose production during insulin waning which occurred at least 135 min earlier with MI as compared to HI (p<0.05). It is concluded that counterregulatory hormones, symptoms and deterioration in cognitive function during hypoglycaemia respond similarly after MI and HI. The biological effect of MI appears greater than that of HI for at least 4 h after the s.c. injection and appears as a good candidate for achieving optimal post-prandial glucose control in IDDM.Abbreviations HI Human insulin - MI monomeric insulin - NEFA non-esterified fatty acid - HGO hepatic glucose production rate - -OH-butyrate -hydroxy-butyrate - IDDM insulin-dependent diabetes mellitus - NIDDM non-insulin-dependent diabetes mellitus